{"id":"NCT01925209","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2013-09-26","primaryCompletion":"2016-01-06","completion":"2016-01-06","firstPosted":"2013-08-19","resultsPosted":"2017-05-12","lastUpdate":"2017-08-11"},"enrollment":251,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Sporadic Inclusion Body Myositis"],"interventions":[{"type":"DRUG","name":"BYM338/bimagrumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"BYM338/bimagrumab 10 mg/kg","type":"EXPERIMENTAL"},{"label":"BYM338/bimagrumab 3 mg/kg","type":"EXPERIMENTAL"},{"label":"BYM338/bimagrumab 1 mg/kg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM).","primaryOutcome":{"measure":"Change From Baseline in 6 Minute Walking Distance (6MWD) Test at Week 52","timeFrame":"Baseline, Week 52","effectByArm":[{"arm":"BYM338/Bimagrumab 10 mg/kg","deltaMin":8.63,"sd":10.934},{"arm":"BYM338/Bimagrumab 3 mg/kg","deltaMin":9.63,"sd":10.77},{"arm":"BYM338/Bimagrumab 1 mg/kg","deltaMin":-10.27,"sd":10.718},{"arm":"Placebo","deltaMin":-8.96,"sd":10.765}],"pValues":[{"comp":"OG000 vs OG003","p":"0.2210"},{"comp":"OG001 vs OG003","p":"0.1909"},{"comp":"OG002 vs OG003","p":"0.9263"}]},"eligibility":{"minAge":"36 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":38,"countries":["United States","Australia","Belgium","Denmark","France","Italy","Japan","Netherlands","Switzerland","United Kingdom"]},"refs":{"pmids":["31397289"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":63},"commonTop":["FALL","MUSCLE SPASMS","DIARRHOEA","CONTUSION","ARTHRALGIA"]}}